The activity of suprofen on nystatin-induced paw oedema in rats.
Subplantar injection of nystatin into the rat paw induces acute paw oedema of long duration. In this test the anti-inflammatory activity of alpha-methyl-4-(2-thienylcarbonyl)benzeneacetic acid (suprofen) has been studied using doses from 1.25 up to 160 mg/kg. The lowest dose significantly reducing paw diameter increases was 2.5 mg/kg; more intense and longer lasting reductions appeared progressively with increasing doses. The dose producing 50% inhibition of diameter increase was 2.70 mg/kg 1 h and 1.5 h after administration (lowest ED50). Comparative lowest ED50-values for simultaneously tested reference compounds were 6.2 mg/kg for indometacin, 34 mg/kg for phenylbutazone and 38 mg/kg for acetyl-salicylic acid. Within the first 2 h after administration suprofen exhibited anti-inflammatory activity from 2 to 14 times as potent as did the reference compounds.
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001241:Aspirin / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D004487:Edema / Q000139:chemically induced / Q000188:drug therapy*; D006614:Hindlimb; D007213:Indomethacin / Q000627:therapeutic use; D008297:Male; D009761:Nystatin; D010653:Phenylbutazone / Q000627:therapeutic use; D010666:Phenylpropionates / Q000627:therapeutic use*; D051381:Rats; D013876:Thiophenes / Q000627:therapeutic use*; D013997:Time Factors
D000893:Anti-Inflammatory Agents; D010666:Phenylpropionates; D013876:Thiophenes; D009761:Nystatin; D010653:Phenylbutazone; D001241:Aspirin; D007213:Indomethacin